Anktiva 400 MCG per 0.4 ML Intravesical Solution

RxCUI: 2682691
RxNorm name: Anktiva 400 MCG per 0.4 ML Intravesical Solution
Display name: Anktiva 400 MCG per 0.4 ML Intravesical Solution
Full name: Anktiva 400 MCG per 0.4 ML Intravesical Solution
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:26

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761336	Anktiva	nogapendekin alfa inbakicept-pmln	351(a)	Rx	2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
ANKTIVA	NOGAPENDEKIN ALFA INBAKICEPT-PMLN	Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.	eae31db8-3e7a-d9e0-708d-74419d1b50ff	2025-06-24	Warnings, Adverse reactions	Exact identifier rxcui: 2682691

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
eae31db8-3e7a-d9e0-708d-74419d1b50ff	Anktiva 400 MCG in 0.4 ML Intravesical Solution [PSN] · 0.4 ML nogapendekin alfa inbakicept-pmln 1 MG/ML Intravesical Solution [Anktiva] [SBD] · 0.4 ML Anktiva 1 MG/ML Intravesical Solution [SY] · Anktiva 400 MCG per 0.4 ML Intravesical Solution [SY]	4	9	These highlights do not include all the information needed to use ANKTIVA safely and effectively. See full prescribing information for ANKTIVA. ANKTIVA® (nogapendekin alfa inbakicept-pmln) solution, for intravesical use Initial U.S. Approval: 2024	20250624